Good
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated content is largely consistent with the provided OPZELURA label excerpts (Sections 5.1–5.5) describing boxed-warning themes and related avoidance/monitoring/discontinuation guidance; however, it also includes some meta/evaluative assertions that are not directly verifiable from the label text provided (e.g., claims about “boxed warning elements” without explicitly quoting boxed-warning wording).
Category Scores
Accurate Statements
Serious infections: avoid OPZELURA in patients with an active, serious infection; closely monitor during and after treatment; interrupt OPZELURA for serious/opportunistic infection or sepsis; do not resume until infection is controlled (5.1).
OPZELURA Prescribing Information Section 5.1 Serious Infections.
TB: no active TB cases in OPZELURA trials; TB cases occurred with oral JAK inhibitors in inflammatory conditions; consider evaluating for latent/active TB prior to administration; monitor during use (within 5.1).
OPZELURA Prescribing Information Section 5.1 Serious Infections (Tuberculosis subsection).
Viral reactivation (e.g., herpes zoster): consider interrupting OPZELURA until the episode resolves (within viral reactivation subsection of 5.1).
OPZELURA Prescribing Information Section 5.1 Serious Infections (Viral Reactivation subsection).
Mortality: a higher rate of all-cause mortality was observed with an oral JAK inhibitor compared with TNF blockers; consider benefits/risks prior to initiating/continuing OPZELURA (5.2).
OPZELURA Prescribing Information Section 5.2 Mortality.
Malignancy/lymphoproliferative disorders: malignancies including lymphomas were observed with JAK inhibitors used for inflammatory conditions; additional risk considerations discussed; periodic skin examinations for non-melanoma skin cancers; limit sun/UV exposure (5.3).
OPZELURA Prescribing Information Section 5.3 Malignancy and Lymphoproliferative Disorders.
MACE: higher rate of MACE (cardiovascular death, non-fatal MI, non-fatal stroke) observed with an oral JAK inhibitor vs TNF blockers; consider benefits/risks for patients with cardiovascular risk factors and advise patients about symptoms; discontinue OPZELURA after MI or stroke (5.4).
OPZELURA Prescribing Information Section 5.4 Major Adverse Cardiovascular Events (MACE).
Thrombosis: thromboembolic events reported; avoid OPZELURA in patients at increased risk; if symptoms occur, discontinue and evaluate/treat appropriately (5.5).
OPZELURA Prescribing Information Section 5.5 Thrombosis.
Unsupported Statements
The evaluation_result that the AI content is “supported” / “adheres_to_fda_labeling” is based on the label, but it is a meta-assessment claim rather than a specific label-backed drug claim.
The provided excerpts contain label content, but do not themselves substantiate the AI’s internal scoring/meta-evaluation statements.
Contradictions
Important Omissions
No explicit boxed-warning wording (the actual boxed warning text) is quoted or directly mapped; only Warnings & Precautions section theme alignment is described.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The substantive drug-safety themes (infection risk/avoidance and interruption guidance, mortality consideration, malignancy and skin cancer monitoring, MACE risk/benefit-risk consideration and discontinuation after MI or stroke, and thrombosis avoidance/discontinuation) are consistent with the provided label excerpts (5.1–5.5).
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Meta-evaluative statements are included without direct label quotation; boxed-warning text is not directly mapped verbatim.
Suggested Improvement
Where possible, cite/quote the actual boxed warning text and map each boxed-warning sentence to the specific corresponding labeled guidance sections (e.g., 5.1–5.5), rather than only summarizing thematic alignment.